Difference between revisions of "Androgen receptor"

From Libre Pathology
Jump to navigation Jump to search
 
(5 intermediate revisions by the same user not shown)
Line 1: Line 1:
'''Androgen receptor''', abbreviated '''AR''', is receptor activated by androgens (testosterone, dihydrotestosterone).
{{ Infobox immunostain
| Name      = {{PAGENAME}}
| Image      =
| Width      =
| Caption    =
| Abbrev    =
| Synonyms  =
| Similar    =
| Clones    =     
| Use        =
| Subspecial = 
| Pattern    = nuclear
| Positive  = [[salivary duct carcinoma]], [[Brenner tumour]], [[apocrine carcinoma of the breast]], [[prostate carcinoma]] (most cases)
| Negative  =
| Other      =
}}
'''Androgen receptor''', abbreviated '''AR''', is receptor activated by androgens ([[testosterone]], dihydrotestosterone).


==Tumours with AR==
==Tumours with AR==
Line 5: Line 21:
*Ovarian [[Brenner tumour]].<ref name=pmid24012099>{{Cite journal  | last1 = Kuhn | first1 = E. | last2 = Ayhan | first2 = A. | last3 = Shih | first3 = IeM. | last4 = Seidman | first4 = JD. | last5 = Kurman | first5 = RJ. | title = Ovarian Brenner tumour: a morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium. | journal = Eur J Cancer | volume = 49 | issue = 18 | pages = 3839-49 | month = Dec | year = 2013 | doi = 10.1016/j.ejca.2013.08.011 | PMID = 24012099 }}</ref>
*Ovarian [[Brenner tumour]].<ref name=pmid24012099>{{Cite journal  | last1 = Kuhn | first1 = E. | last2 = Ayhan | first2 = A. | last3 = Shih | first3 = IeM. | last4 = Seidman | first4 = JD. | last5 = Kurman | first5 = RJ. | title = Ovarian Brenner tumour: a morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium. | journal = Eur J Cancer | volume = 49 | issue = 18 | pages = 3839-49 | month = Dec | year = 2013 | doi = 10.1016/j.ejca.2013.08.011 | PMID = 24012099 }}</ref>
*[[Apocrine carcinoma of the breast]] - usu. smaller tumours.<ref name=pmid16045781>{{Cite journal  | last1 = Honma | first1 = N. | last2 = Takubo | first2 = K. | last3 = Akiyama | first3 = F. | last4 = Sawabe | first4 = M. | last5 = Arai | first5 = T. | last6 = Younes | first6 = M. | last7 = Kasumi | first7 = F. | last8 = Sakamoto | first8 = G. | title = Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast. | journal = Histopathology | volume = 47 | issue = 2 | pages = 195-201 | month = Aug | year = 2005 | doi = 10.1111/j.1365-2559.2005.02181.x | PMID = 16045781 }}</ref>
*[[Apocrine carcinoma of the breast]] - usu. smaller tumours.<ref name=pmid16045781>{{Cite journal  | last1 = Honma | first1 = N. | last2 = Takubo | first2 = K. | last3 = Akiyama | first3 = F. | last4 = Sawabe | first4 = M. | last5 = Arai | first5 = T. | last6 = Younes | first6 = M. | last7 = Kasumi | first7 = F. | last8 = Sakamoto | first8 = G. | title = Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast. | journal = Histopathology | volume = 47 | issue = 2 | pages = 195-201 | month = Aug | year = 2005 | doi = 10.1111/j.1365-2559.2005.02181.x | PMID = 16045781 }}</ref>
*[[Prostate carcinoma with amphicrine features]].<ref name=pmid28756619>{{Cite journal  | last1 = Prendeville | first1 = S. | last2 = Al-Bozom | first2 = I. | last3 = Compérat | first3 = E. | last4 = Sweet | first4 = J. | last5 = Evans | first5 = AJ. | last6 = Ben-Gashir | first6 = M. | last7 = Mete | first7 = O. | last8 = van der Kwast | first8 = TH. | last9 = Downes | first9 = MR. | title = Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumours of primary prostatic origin? | journal = Histopathology | volume = 71 | issue = 6 | pages = 926-933 | month = Dec | year = 2017 | doi = 10.1111/his.13330 | PMID = 28756619 }}</ref>
==Antibodies==
Various clone exist and they target different regions/variants; an incomplete list includes:
*AR N-terminus.
*AR C-terminus.
*AR v7.


==See also==
==See also==
*[[Immunohistochemistry]].
*[[Immunohistochemistry]].
*[[Enzalutamide]].
*[[Abiraterone]].


==References==
==References==

Latest revision as of 13:09, 18 March 2019

Androgen receptor
Immunostain in short
Normal staining pattern nuclear
Positive salivary duct carcinoma, Brenner tumour, apocrine carcinoma of the breast, prostate carcinoma (most cases)

Androgen receptor, abbreviated AR, is receptor activated by androgens (testosterone, dihydrotestosterone).

Tumours with AR

Antibodies

Various clone exist and they target different regions/variants; an incomplete list includes:

  • AR N-terminus.
  • AR C-terminus.
  • AR v7.

See also

References

  1. Fan, CY.; Wang, J.; Barnes, EL. (Apr 2000). "Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature.". Am J Surg Pathol 24 (4): 579-86. PMID 10757407.
  2. Kuhn, E.; Ayhan, A.; Shih, IeM.; Seidman, JD.; Kurman, RJ. (Dec 2013). "Ovarian Brenner tumour: a morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium.". Eur J Cancer 49 (18): 3839-49. doi:10.1016/j.ejca.2013.08.011. PMID 24012099.
  3. Honma, N.; Takubo, K.; Akiyama, F.; Sawabe, M.; Arai, T.; Younes, M.; Kasumi, F.; Sakamoto, G. (Aug 2005). "Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.". Histopathology 47 (2): 195-201. doi:10.1111/j.1365-2559.2005.02181.x. PMID 16045781.
  4. Prendeville, S.; Al-Bozom, I.; Compérat, E.; Sweet, J.; Evans, AJ.; Ben-Gashir, M.; Mete, O.; van der Kwast, TH. et al. (Dec 2017). "Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumours of primary prostatic origin?". Histopathology 71 (6): 926-933. doi:10.1111/his.13330. PMID 28756619.